Table 11

Quantitative syntheses of incidence of participants attaining ATP III LDL-c targets, for ezetimibe plus statin combination therapy compared with statin monotherapy

Number of trials reporting outcomeNumber of participants in relevant treatment groupsNumber of participants with eventsOdds ratioLower CIUpper CI
Relative probability of attaining ATPIII LDL-c goal
All trials47,112,114–118,121,126,127,129,130,140,142,144,148,149,151,156,167,168,193,194231594411329---
Participants requiring intensive lipid lowering therapy47,112,114–118,121,140,142,144,148,149,151,167,168,193,1941877315342---
Simvastatin
Lower dose statin in combination versus higher dose monotherapy
Participants requiring intensive lipid lowering therapy47,121,151
3652386---
Simvastatin
Lower dose statin in combination versus higher dose monotherapy fixed dose and/or fixed titration only
Participants requiring intensive lipid lowering therapy121,151
22951497.214.3012.08
Participants with diabetesmellitus115,117,118,121,144,149,167,193,194943402720---
Simvastatin
Lower dose statin in combination versus higher dose monotherapy
Participants with diabetes mellitus 121
170414.791.7213.35
Participants with established vascular disease 114–116,140,149,168619221131---
Participants of Hispanic descent 1171113547.823.1419.45
Participants of African descent 11712081093.471.906.33
Female participants only2189104---

Abbreviations: ATP III = Third Adult Treatment Panel of the National Cholesterol Education Program, CI = 95% confidence interval, LDL-c = low density lipoprotein cholesterol

From: 3, Results

Cover of Comparative Effectiveness of Lipid-Modifying Agents
Comparative Effectiveness of Lipid-Modifying Agents [Internet].
Comparative Effectiveness Reviews, No. 16.
Sharma M, Ansari MT, Soares-Weiser K, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.